Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $8.7 million.

  • Niagen Bioscience's Accumulated Expenses fell 9.30% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 9.30%. This contributed to the annual value of $7.8 million for FY2024, which is 17.66% down from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Accumulated Expenses is $8.7 million, which was up 17.87% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Accumulated Expenses ranged from a high of $10.5 million in Q1 2024 and a low of $5.6 million during Q2 2021.
  • For the 3-year period, Niagen Bioscience's Accumulated Expenses averaged around $8.8 million, with its median value being $8.7 million (2025).
  • Per our database at Business Quant, Niagen Bioscience's Accumulated Expenses soared by 36.07% in 2023 and then fell by 17.66% in 2024.
  • Over the past 5 years, Niagen Bioscience's Accumulated Expenses (Quarterly) stood at $6.5 million in 2021, then grew by 13.21% to $7.3 million in 2022, then rose by 29.39% to $9.5 million in 2023, then decreased by 17.66% to $7.8 million in 2024, then decreased by 9.30% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $7.4 million for Q2 2025, and $9.1 million during Q1 2025.